August 23, 2016 7:07am
… Up, down, round and round, low volume, high volatility, financing discounts and dilution
“Our” universe’s behavior mystifies investors if they choose to let it
… Understand, there is always a myopia related to share pricing
Companies in my headlights: FATE, JUNO, KOOL, PSTI and RGNX
Futures and indexes are UP
I answer one question; in which company should investors put, keep and commit their money!
Where is today’s market going?
Subscribe and find out!
Where do investors turn for insight and perspective - I say what others won't, so you can do what others can't!
Indexes and ETFs: The IBB (+0.44%), IWM (+0.31), XLV (+0.01%) and the XBI (+0.07) are UP
Dow futures are UP +0.24% and NASDAQ futures are UP +0.28%
U.S. stock index futures ticked higher on Tuesday, as investors prepared themselves for a further set of earnings and looked ahead to a key speech by the Fed's Chair.
European stocks extended gains buoyed by data which showed that the euro zone economy had yet to feel a negative impact from the 'Brexit' vote.
Asian markets were mixed with the Japanese market ending lower as stocks came under pressure due to a weaker dollar buoying the yen.
Data docket: the New Home Sales data and Richmond Fed survey are due out at 10.00 a.m. ET. Markit's Flash US Manufacturing PMI is also expected to be released in the morning.
The stem, cell, gene and regenerative therapy (SCG&RT) sector closed POSITIVE on Monday, NEGATIVE on Friday, POSITIVE on Thursday, NEGATIVE on Wednesday and last Tuesday.
The SCG&RT sector’s record after the last 5 days (of 43 covered companies):
- Monday closed POSITIVE with 14 decliners, 27 advancers and 2 flats;
- Friday closed NEGATIVE with 29 decliners, 13 advancers and 1 flat;
- Thursday closed POSITIVE with 14 decliners, 26 advancers and 3 flats;
- Wednesday closed NEGATIVE with 33 decliners, 9 advancers and 1 flat;
- Last Tuesday closed NEGATIVE with 28 decliners, 12 advancers and 3 flats;
Remembering Monday’s closing post, “Recent performance reinforces the randomness of the sector. Why complain, it is a traders market in “our” universe! Stocks continued to trade in tight ranges amid low but, sweeling volume still, with increased volatility.”
- Related to today’s pre-open’s title, myopia presents with blurry distance vision, but generally gives good near vision.
Investor’s near-sightedness is the most common problem and rates have increased which is one of the most common causes of portfolio loss.
- Reiterating, the stem, cell, gene and regenerative therapy stocks ended higher Monday after Friday being oversold after Thursday’s run-up post Wednesday’s run-down that identified fundamentals being weaken and resistance high.
It is the dilemma of investing in a development company and a function of the buying and selling at opportune timing and those decisions MUST be made if investors are going to stay, as I say … along for the ride.
You’ve made it to the office, turned on the monitor, having just gotten your coffee and it hits you - what could be today’s trades?
Watch list:
- The iShares Nasdaq Biotechnology (IBB) closed Monday up +1.96% and is UP +0.44% in Tuesday’s pre-market;
- The SPDR S&P Biotech ETF (XBI) closed Monday up +2.67% and is UP +0.07% in Tuesday’s pre-market;
- The Health Care Select Sector SPDR ETF (XLV) closed up Monday +0.20% and is DOWN -0.04% in Tuesday’s pre-market;
- The iShares Russell 2000 (IWM) closed up +0.21% on Monday and is UP +0.31% in Tuesday’s pre-market.
Companies in my headlights:
Cesca Therapeutics (KOOL) closed UP +$0.54 to $4.70. Spikes and bounces are prevalent in this equity, as evident by last week’s pricing Friday’s $4.16, $3.88, Wednesday’s $3.89, $3.90 Monday’s $4.20 and the previous Friday’s $3.96. The aftermarket indication is negative -$0.03 – Maintaining SELL;
Juno Therapeutics (JUNO) closed UP +$0.29 to $33.42. Another company with “flux” being its middle name, Last Friday’s $33.13, Thursday’s $34.02, Wednesday’s $33.84, Tuesday’s $34.21 and last Monday’s $32.66. The aftermarket indication is negative -$0.32 – SELL;
Fate Therapeutics FATE) closed DOWN -$0.03 to $2.89 after being FLAT on Friday’s at $2.92. New highs could prompt a trader target after the week’s range of $2.73 to $2.92 and 7/25’s $1.68. Like the company and the management team but, the market speaks to itself – Maintaining SELL;
Pluristem (PSTI) closed DOWN -$0.06 to $1.67. After a precipitous dive, questions arise about new highs after increasing levels post Friday’s $1.73, Thursday’s $1.74, Wednesday’s $1.68, Tuesday’s$1.66 and last Monday’s $1.59 following the previous Friday’s $1.54 – Maintaining SELL;
Regenxbio (RGNX) closed UP +$0.89 to $13.57. The chart is peaking, after Friday’s $12.68, Thursday’s $12.10, Wednesday’s $12.11, $12.19, last Friday’s $12.30 and the previous Monday’s $11.50. The target has a bull eyes for upsides in these “shallow” summer weeks - SELL
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
